New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
08:02 EDTCSIICardiovascular Systems enrolls first patient in COAST study
Cardiovascular Systems announced that the first patient has been enrolled in its Coronary Orbital Atherectomy System Trial, or COAST, trial. Taking place in the United States and Japan, the study is designed to assess the safety and efficacy, as well as economic outcomes, of CSI’s new micro crown Orbital Atherectomy System in treating severely calcified coronary lesions in patients suffering from Coronary Artery Disease. Dr. Arthur Lee, North Florida Regional Medical Center, Gainesville, Fla., performed the first procedure. Building on CSI’s ORBIT II study, the first study designed to enroll severely calcified lesions that are typically excluded from all major trials but commonly seen in the real world cases, COAST is a prospective, single-arm, multi-center, global, investigational study designed to evaluate the safety and efficacy of CSI’s new micro crown OAS in these difficult to treat lesions.
News For CSII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2015
07:43 EDTCSIICMS panel removes Cardiovascular Systems overhang, says Leerink
Leerink analyst Danielle Antalffy says the CMS Medicare Evidence Development & Coverage Advisory Committee panel on peripheral arterial disease removes a near-term overhang on shares of Cardiovascular Systems. The company should return to 20%-plus growth with both outpatient reimbursement and CMS panel risk now addressed, Antalffy tells investors in a research note. She keeps an Outperform rating on the stock with a $45 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use